Viral vectors available for gene therapy are either inefficient or suffer from safety concerns for human applications. Foamy viruses are nonpathogenic retroviruses that offer several unique opportunities for gene transfer in various cell types from different species. In this report, we describe the use of simian foamy virus type 1 (SFV-1) vector to examine the efficacy of therapeutic genes. Hairpin short-interfering RNA (siRNA) that targets the simian immunodeficiency virus (SIV) rev/env was placed under the control of the PolIII U6 snRNA promoter for expression and screened for silencing target genes using cognate target -reporter fusions. We have identified an effective siRNA (designated R2) which reduces the rev and env gene expression by 89% and 95%, respectively. Using the simian foamy virus type 1 (SFV-1) based vector, we delivered the PolIII expressed R2 siRNA into cultured cells and challenged with SIV. The results show that the R2 siRNA is a potent inhibitor of SIV replication as determined by p27 expression and reverse transcriptase assays. Vectors based on a non-pathogenic SFV-1 vector may provide a safe and efficient alternative to currently available vectors, and the SIV model will help devise protocols for effective anti-HIV gene therapy. D
Introduction
One of the major problems in gene therapy is the low transduction efficiency in target tissues. Although various vector systems are available, there is still a growing demand for a suitable gene transfer vehicle. Currently available vehicles for gene transfer are either inefficient or potentially unsafe for human gene therapy applications. Foamy viruses offer a fresh alternative vector system for gene transfer. These viruses are members of the spumavirus subfamily of retroviruses and have several inherent features that make them ideal for constructing retroviral vectors to deliver heterologous genes in many species and cell types. First, foamy viruses can be propagated efficiently in various cell types of several species such as cultured epithelial and fibroblast cells as well as lymphoid and neural originated cells which support the growth of foamy viruses (Hill et al., 1999; Mergia and Heinkelein, 2003; Mergia et al., 1996) . Each foamy virus isolate is known to infect several mammalian species from which virus can be recovered from many organs (Hooks and Detrick-Hooks, 1981) . Secondly, to date, no disease has been connected to foamy virus in naturally as well as experimentally infected animals (Flugel, 1991; Linial, 2000; Mergia and Luciw, 1991; Weiss, 1988) . Humans are not natural hosts of foamy viruses; however, hunters in Central Africa and occupational infections with primate foamy virus isolates have been reported (Callahan et al., 1999; Heneine et al., 1998; Schweizer et al., 1997; Schweizer et al., 1995; Wolfe et al., 2004) . Animal caretakers accidentally infected with SFV remain healthy with no secondary human to human transmission being detected (Heneine et al., 1998) . Thirdly, reverse transcription occurs late in the replication cycle of foamy viruses before the virion is released from the infected cell and that at least 20% of the released virions contain fully reverse transcribed infectious DNA (Enssle et al., 1997; Yu et al., 1996 Yu et al., , 1999 (Patton et al., 2004; Trobridge and Russell, 2004) . The foamy virus genome persists in nondividing cells for at least 10 days. Whether the genome stays episomally in none dividing cells remains to be determined. Nevertheless, the high transduction in non-dividing cells will make foamy virus an effective vector compared to retroviral vectors that require cell division for efficient transduction.
Principle information for the design of foamy virus vectors is worked out and several foamy virus vectors that efficiently transduce a variety of cell types from different species are available (Reviewed in Mergia and Heinkelein, 2003) . Foamy virus vectors can efficiently transduce human hematopoietic cells obtained from umbilical cord blood at low multiplicity of infections (Josephson et al., 2002) . The severe combined immunodeficiency (SCID) recipients of transduced CD34+ human hematopoietic cells express the vector-encoded transgene in all hematopoietic cell lineages analyzed. Transduction efficiencies in the range of 64-92% in SCID repopulating cells using the prototype foamy virus 1 (PFV, originally human foamy virus) vector, containing a transgene under the control of murine stem cell virus promoter were reported, indicating that foamy virus vectors are ideal vehicles for human gene therapy (Josephson et al., 2002) . Furthermore, a comparative study of transduction efficiencies in CD34+ cells revealed that foamy virus vectors are superior to that of HIV vectors (Leurs et al., 2003) . Efficient transduction of foamy virus vector into blood cells has implications for the use of foamy virus based vectors in immunodeficiency virus gene therapy. In this report, we provide the use of a simian foamy virus type 1 (SFV-1) vector to examine the efficacy of therapeutic genes and thus demonstrate inhibition of simian immunodeficiency virus replication in cells transduced with SFV-1 vectors containing siRNA molecules.
Results

Inhibition of SIV Rev expression by siRNAs
Short hairpin siRNAs that target the rev gene selected from three different regions (R1, R2 and R3, Table 1 ) were designed as previously described (Paul et al., 2002) . Each siRNA was placed under the control of the PolIII U6 snRNA promoter for expression. The expression of siRNAs was monitored by Northern blot analysis; a representative Northern blot for siRNA expression from 293T cells transfected with 2 Ag of plasmid containing the R2 siRNA expression cassette is shown in Fig. 1A . To initially test efficacy of these siRNAs, we constructed a Rev-GFP expression cassette that contains the coding sequence of rev with its expression serving as a substrate for all three siRNAs. A 1:200 substrate to siRNA plasmid ratio, for each construct, was co-transfected into 293T cells and the level of GFP expression was monitored daily for level of fluorescence by observing under a UV-microscope. Cells were harvested 2 days post-transfection for FACS analysis. Controls included samples from cells only mocktransfected and pSP72 co-transfected with pRevGFP. The level of fluorescence was quantified relative to cells transfected with pRevGFP and pSP72 (Fig. 1B) . The results are an average of three independent experiments. In cells treated with the R2 siRNA, fluorescence was reduced by 89%. An increase in fluorescence was observed in cells transfected with pU6R1 or pU6R3 relative to pSP72 indicating that the R1 and R3 siRNAs had no activity on their cognate substrate RNA molecules. We observed no cytotoxicity side effects due to siRNA introduction as determined by comparing cells transfected with plasmids containing or lacking siRNA (data not shown). Interestingly, GFP expression increased by 2.5-fold in cells transfected with pU6R1 plasmid compared to cells transfected with pSP72. This result implies that the R1 siRNA had activity that enhances rev-GFP expression by a mechanism that is not currently clear. The GFP expression in cells transfected with pU6R3 is also slightly elevated. R2 siRNA activity was further examined on the substrate in samples transfected with different concentrations of pU6R2 plasmid while maintaining the same concentration of substrate. The results showed a reduction in fluorescence with increasing amount of DNA, indicating the effect of siRNA on the substrate Rev-GFP correlated with the amount of effector input DNA (Fig. 1C) . However, with a 50 times increase in DNA concentration, there was a 2-3-fold change in inhibition of target molecules, indicating that the decrease in target molecule did not correlate in a linear fashion with increased amounts of DNA. The lack of linear correlation may be due to the differences in promoter strength between CMV and U6. To examine that the low level GFP expression observed in siRNA treated cells was due to activity on target RNA molecules, the levels of Rev-GFP transcripts were examined by Northern blot analysis (Fig. 2) . RNA samples isolated from cells co-transfected with a plasmid containing each siRNA expression cassette and pRev-GFP were hybridized to a GFP probe. RNA blots were also hybridized with actin probe to monitor and normalize for RNA recovery. The Rev-GFP transcripts were not targeted by R1 or R3 siRNAs confirming the results of GFP expression at the protein level. Similar to the expression at the protein level, the mRNA level was also elevated in cells that received the R1 or R3 siRNA. In cells transfected with R2 siRNA, however, the Rev-GFP expression was significantly reduced thus validating the results of the protein expression. The R2 siRNA, therefore, is an effective siRNA which acts on its substrate RNA molecule.
Inhibition of SIV Env expression by the R2 siRNA
The target for siRNA R2 is in exon 2 of SIV rev (nucleotide position 9185 -9203) which also contains part of the env sequence. To determine whether the R2 siRNA can also silence Env expression, the env sequence was placed in frame with GFP to create a fusion Env-GFP protein (pEnvGFP). The level of Env-GFP expression was examined in cells co-transfected with the R2 siRNA expression cassette (pU6R2) or a control plasmid which lacks the siRNA (pSP72). When a ratio of DNA tranfection of Env-GFP:R2 siRNA of 1:66 was used, fluorescence was reduced by 87% compared to cells receiving the control pSP72 which lacked the siRNA expression cassette (Fig. 3) . The effect of the R2 siRNA was more pronounced when increased amount of the pU6R2 was used. When a ratio of Env-GFP:R2 siRNA of 1:200 was co-transfected, the level of fluorescence was reduced by 95%. The R2 siRNA, therefore, affects the expression of both Rev and Env proteins.
Inhibition of SIV replication in cells transduced with SFV-1 vector carrying siRNAs
Recombinant SFV-1 vectors containing siRNAs were constructed in order to determine the efficacy of siRNAs delivered via foamy virus vector on SIV replication (Fig. 4) . Since the R2 siRNA effectively inhibited the expression of both Rev-GFP and Env-GFP proteins, we placed the R2 siRNA expression cassette in an SFV-1 vector (pSFV-1U6R2/zeo). The pSFV-1U6R2/zeo was transfected along with packaging plasmids into 293T cells generating vector particles used to infect CEMx174 cells which are susceptible to SIV infection. As a control, cells receiving no SFV-1 vector were used (mock). The transduced cells were challenged with SIV at an moi of 0.001. Supernatants from the infected cells were harvested every 2 days for 17 days to determine the levels of virus production by monitoring for reverse transcriptase (RT) enzyme activity and the capsid p27 protein by ELISA. As shown in Fig. 5 , in the mock transduced cells, SIV replication was detected 3 days post-infection increasing exponentially thereafter until cell lysis began. In cells transduced with the R2 siRNA, the value of RT activity and p27 protein began to drop at day 9 compared to mock transduced cells with inhibition of virus replication reaching 68%. The reduction in RT and p27 remained until day 17 indicating that the SFV-1 vector delivered R2 siRNA had effectively inhibited SIV replication.
The reason for the delay of the inhibitory effect of R2 until day 9 may have to do with the time taken to accumulate enough siRNA that had an impact on a replicating virus. The R2 siRNA, therefore, is an efficient inhibitor of SIV replication and can substantially reduce virus replication.
We further examined the efficacy of the SFV-1 siRNA transduction to suppress virus replication in cells in which an SIV infection had been established. CEMx174 cells were infected with SIV239 at an moi of 0.005, and at 24 h postinfection, the cells were then transduced with SFV-1 vector containing the R2 siRNA at an moi of 50. As controls, infected cells receiving no SFV-1 vector (mock) or SFV-1 vector that express GFP without siRNA were used. Supernatants from the cells were harvested every 3 days beginning day 6 postinfection until day 15 and virus production was monitored by RT enzyme activity. As shown in Fig. 6 , SIV replication in control cells was detected at day 6 increasing exponentially until cell lysis began. In cells treated with the R2 siRNA, Fig. 4 . Schematic representation of SFV-1 vector containing siRNA expression cassette. The siRNA expression cassette was inserted upstream of the internal CMV promoter in the SFV-1 vector. Each siRNA was expressed under the control of PolIII U6 snRNA promoter. The sense and antisense strands of the siRNA were separated by four nucleotides and five T nucleotides were attached at the 3V end as a termination sequence. inhibition of virus replication was observed at day 6 and reduction in replication reaching 73% or 80% when compared to controls of SIV harvested from mock transduced or SFV-1 vector expressing GFP, respectively. SFV-1-mediated siRNA transduction was therefore also effective in cells where SIV infection was established.
Discussions
We have established the basis for the utility of SFV-1 vectors in gene therapy applications. The observation that no disease is associated with foamy viruses argues that foamy virus vectors can be safe for human gene therapy. Foamy virus vectors can efficiently transduce a variety of cells including clinically important cell types. In this study, we have shown that vectors developed from simian foamy virus containing siRNAs can effectively inhibit SIV replication. Using direct transfection methods, the R2 siRNA that targets the SIV rev and env genes efficiently reduced the expression of Rev-GFP and Env-GFP fusion proteins. The replication of SIV was significantly inhibited in cells transduced with SFV-1 vector carrying the R2 siRNA.
Direct transfection of sense and antisense siRNA expression cassettes that target HIV showed inhibition of target-GFP fusion protein expression by 70 -90% (Lee et al., 2002; Park et al., 2003) . The hairpin type siRNA is equally effective to that of the duplex made from independent complementary ssRNAs. Our hairpin type R2 siRNA was also effective and showed an 89% to 95% fluorescence reduction in the SIV rev-GFP and env-GFP fusion expressions. The R2 activity was, therefore, comparable to that which was observed for the HIV studies. Lentivirus vector-mediated delivery of siRNAs that target HIV showed up to a 1 -3 log reduction in virus replication Li et al., 2003) . Similar results were also obtained with siRNAs delivered via an AAV vector (Han et al., 2004) . The lower efficacy observed with foamy virus vector delivered siRNA may have to do with less efficient gene delivery into CEMx174 cells. Recent experiments revealed that the bet gene product is important in blocking the antiviral activities of cellular APOBEC3 protein (Lochelt et al., 2005; Russell et al., 2005) . The lack of the bet gene product from the foamy vector system may reduce gene delivery into CEMx174 cells, while in 293T cells where APOBEC3 is absent, vector production and transduction are efficient. Transduction of primate CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE/TAR decoy or antisense/ribozyme inhibits HIV replication in myelomonocytic and differentiated T cells produced in long-term culture (Bahner et al., 1996; Bonyhadi et al., 1997; Rosenzweig et al., 1997; Su et al., 1997 ). These findings demonstrate the ability of antiviral strategies to inhibit HIV replication in primary myelomonocytic and T cells after transduction of CD34+ progenitor cells and expansion. Furthermore, after reconstitution of human bone marrow cells implanted in SCID mice (SCID-hu bone) with the transduced hematopoietic stem cells, a significant number of donor derived CD14+ bone marrow cells were found to express the anti-HIV molecules Su et al., 1997) . When donor-derived thymocytes from reconstituted SCID-hu are infected with HIV, in vitro, significant inhibition of virus replication was observed Su et al., 1997) . Similarly, progeny of CD34+ hematopoietic progenitor cells transduced with siRNAs show resistance to HIV challenges (Banerjea et al., 2003) .
While these studies achieved variable levels of antiviral gene activities, a major limitation with most anti-HIV gene therapy studies is the lack of an effective safe vector that will efficiently deliver antiviral genes into the host. Although lentivirus vectors are refined and promising, vectors based on a pathogenic virus for human gene therapy will always remain a public concern. In general, the discovery of leukemia in 2 of 11 children receiving gene therapy using a retroviral vector has caused serious concern about the adverse effect of retroviral vectors in gene therapy applications (Hacein-Bey-Abina et al., 2003; Marshall, 2002 Marshall, , 2003 . Comparative studies to evaluate integration sites between MuLV and HIV in hematopoietic cells revealed reduced level of risk for genotoxic events with lentivirus vectors (De Palma et al., 2005) . Contrary to this observation, another study demonstrated the development of liver tumor in mice treated intravenously with a lentivirus vector (Themis et al., 2005) . Since foamy virus genomes integrate into the host genome, the potential to disrupt or activate a gene exists. However, studies of foamy virus genome integration analysis into the host chromosomes are required to demonstrate if there are integration preferences that reflect the non-pathogenic phenotype of foamy virus infection. Our results showed suppression of SIV replication with the delivery of siRNAs into target cells by non-pathogenic foamy virus vectors. In addition to being non-pathogenic, foamy virus vectors can efficiently transduce human hematopoietic cells and comparative studies have indicated that foamy virus vectors are superior in transducing CD34+ cells (Leurs et al., 2003) . Therefore, SFV-1-mediated siRNA delivery into human hematopoietic stem cells for HIV therapy will have safe and effective clinical applications. Protocols for novel HIV therapy can be established through the SIV system. The rush to perform antiviral gene therapy experiments in humans without developing effective safe vectors and protocols could hamper progress. Novel vector systems, such as SFV-1, for the SIV gene therapy model can establish a basis for effective anti-HIV gene therapy.
Materials and methods
Cell cultures
The 293T (human embryonic kidney fibroblasts) and CEMx174 (human T cell line) cell lines were obtained from American Type Culture Collection (Rockville, Md.). Cells were grown in Dulbecco's modified Eagle medium or in RPMI medium for 293T cells or CEMx174 cells, respectively, supplemented with antibiotics and 10% fetal calf serum.
Construction of plasmids
The plasmid pRevGFP was constructed by inserting the SIV rev cDNA (nucleotide positions 6784-6853 spliced in to 9062 -9309) upstream of a coding sequence of GFP in frame. Similarly, to generate an SIV env-GFP fusion protein, the coding region of SIV env (nucleotide sequence position 6706 -9374) was cloned upstream to the GFP coding region creating the plasmid pEnvGFP. The fusion proteins were expressed under the control of the human cytomegalovirus (CMV) immediate early gene promoter. Hairpin siRNAs that target different regions in rev (R1, R2, R3) were chemically synthesized with a four nucleotide gap between sense and antisense having the restriction enzyme sites SalI and XbaI attached at the 5V and 3V ends for cloning, respectively. The target sequences for each of the siRNAs are shown in Table 1 . The pTZU6+27 plasmid (Paul et al., 2002) which contained the PolIII U6 snRNA promoter for siRNA expression was provided by David R. Engelke of the University of Michigan (Ann Arbor, MI). To create expression cassettes for each siRNA, the PolIII U6 snRNA promoter was removed from pTZU6+27 with restriction enzyme digests of BamHI and XhoI and cloned into pSP73 creating the plasmid pU6. Each siRNA was cloned into SalI-XbaI sites of pU6 while attaching five T termination nucleotides at the 3V end of the hairpin structure as described previously (Paul et al., 2002) , thus generating expression cassettes of pU6R1, pU6R2 and pU6R3.
A simian foamy virus type 1 (SFV-1) vector, pSFV-1AMgp/ zeo containing a GFP expression cassette, was used to deliver and express the siRNAs in the target cells (Fig. 4) . pSFV1AMgp/zeo was derived from pCCGL. The construction of pCCGL was described previously (Park et al., 2002) . The translation initiation ATG codons were destroyed in both gag and pol genes in pCCGL to create pCCGLDgp. In pSFV-1U6R2, the R2 siRNA expression cassette was cloned into pSFV-1AMgp upstream the internal CMV promoter. The pSFV-1U6R2 was modified by replacing the CMV-GFP expression cassette with a CMV promoter controlling the expression of the zeocine and GFP genes (pSFV-1U6R2/zeo). A ribosomal entry sequence (IRES) was placed between zeocine and GFP to allow efficient expression of GFP. All constructs were confirmed by sequencing double-stranded DNA templates using the Perkin-Elmer Applied Biosystem Division (PE/ ABD) 373A automated sequencer.
DNA transfections
Transfections of 293T cells were carried out in six well plates by the liposome-mediated method with the reagent LipofectAMINE according to the manufacturer's recommendations (Life Technologies, Inc., Gaithersburg, Md.). Cells were seeded at a density of 4.5 Â 10 5 in 6-well plates and cotransfected with 2 Ag of an effector plasmid for siRNA expression and varying concentrations (0.01 -0.5 Ag) of substrate plasmid containing the expression cassette for the target-GFP fusion protein. The medium was replaced with fresh DMEM containing 10% FBS 24 h after transfection. Cells were harvested 2 days post-transfection to determine the effect of siRNA on the substrate RNA molecule. Cells were prepared for flow cytometry analysis to determine the level of GFP expression.
RNA blot hybridization
Total RNA was extracted from 293T cells co-transfected with siRNA and target expression plasmids using QIAGEN's RNeasy kit (QIAGEN Inc., Valencia, CA). The RNA was treated with 10 units of RNAse-free DNAse (Ambion, Austin, TX) for 30 min at 37 -C. Ten micrograms of total RNA was fractionated on a 1.2% agarose gel containing 2.2 M formaldehyde and transferred to a nylon membrane (MagnaGraph; Micron Separations Inc., Minnetonka, MN) for hybridization. The membrane was hybridized under a stringent condition to [a- 32 P]dCTP-labeled DNA fragment representing GFP or PCR amplified h-actin fragment as a control. To isolate small size RNA molecules, 293T cells were harvested 2 days after transfection of siRNA expression plasmids and RNA was isolated using the MirVana RNA isolation kit (Ambion, Inc., Austin, TX). Ten micrograms of RNA was denatured with 1 M glyoxal and 50% DMSO in 10 mM sodium phosphate buffer, pH 7.0, at 50 -C for an hour. RNAs were eluted on a 3% Nusieve (3:1) agarose gel in sodium phosphate buffer (pH 7.0). The RNA was transferred to HybondÀ N+ membrane (Amersham Bioscience UK Limited, England) overnight by capillary transfer and hybridized to the [g-32 P]ATP-labeled 19 nucleotide R2-specific antisense probe. For the detection of internal control RNA, U6 RNA-specific antisense oligonucleotide, 5V-TGCTAATCTTCTCTGTATCGT-3V was used as a probe after labeling the 5V end with [g-32 P]ATP.
Production of packaged SFV-1 vectors and transduction
SFV-1 vector particles were produced by co-transfecting 293T cells with SFV-1 vector containing anti-SIV sequences (Fig. 4) and the packaging plasmid CRU5GPEpolA. The construction of CRU5GPEpolA was described previously (Park et al., 2002) . To enhance foamy virus vector production, cells were stimulated 6 -8 h post-transfection with 10 mM sodium butyrate (Sigma-Aldrich, St. Louis, MO) for 12 h and supernatants were harvested 4 days post-transfection. Viral supernatants were clarified by centrifugation at 5000 rpm for 20 min then by passaging through a 0.45 Am filter. The vector particles were further concentrated 100-fold by using the Apollo Centrifugal Spin Concentrators, 70 kDa (Orbital Biosciences, Topsfield, MA). The amounts of SFV-1 vector produced were titered on fresh 293T cells plated at a density of 2.5 Â 10 4 per well in 24 well plates. Seventy-two hours after infection, cells were monitored and scored for GFP fluorescent under a microscope with UV light source. Transduction of CEMx174 cells was performed by spin-inoculation as previously described (Mergia et al., 2001) . Briefly, cells were seeded at a density of 5 Â 10 5 per well, centrifuged at room temperature for 10 min at 2500 rpm and resuspended in 300 Al [multiplicity of infection (moi) of 4] of SFV-1 vector particles. The resuspended cells were then spun at 1500 rpm for 1 h as described previously (Bahner et al., 1996; Bunnell et al., 1995) and the infection procedure was repeated 8 h later. Four days postinfection, the culture medium was replaced with RPMI supplemented with 400 Ag/ml of zeocine to enrich for transduced cells.
SIV virus preparation and challenges
The SIVmac239 provirus DNA was transfected into CEMx174 cells using the DEAE-Dextran method as previously described to produce viral particles (Naidu et al., 1988) . Virus replication was monitored by cytopathic effect and reverse transcriptase assay. RT activities of the culture supernatant from SIV challenge experiments were analyzed as described previously (Willey et al., 1988) . Briefly, 10 Al of supernatant was taken after centrifuging virus infected cell culture for 10 min at 10,000 rpm to remove cell debris. The supernatant was mixed in 50 Al of 50 mM Tris -HCl (pH 8), NP-40 (0.1%), dithiothreitol (1 mM), KCl (40 mM), EGTA (0.5 mM), MgCl 2 (1 mM) and BSA (100 Ag/ml). RT activity was assayed in triplicate with 3 H-dTTP as a precursor and poly rA/oligo dT as a template/primer. TCID50 values were determined by serially diluting supernatants of each virus stock, infecting CEMx174 cells and counting syncytia formed cells.
The CEMx174 cells transduced with SFV-1 vector containing anti-SIV sequences were challenged with SIV at a multiplicity of infection of 0.001 using the DEAE-dextran method as reported previously with minor modifications (Vzorov and Compans, 2000) . Briefly, cells were treated with 20 Ag/ml DEAE-dextran for 2 h and washed with RPMI medium before SIV infection. Two hours after infection, the medium was replaced with fresh RPMI medium supplemented with 10% FBS. The SIV infected cells in triplicate wells of a 6-well plate were incubated at 37 -C under 5% CO 2 atmosphere and culture supernatants were collected every 2 days. The efficacy of SFV-1 siRNA vector was also examined in CEMx174 cells in which an SIV infection was established with SIV239 at an moi of 0.005. Infected cells were transduced with moi 50 of SFV-1 vector containing anti-SIV siRNA 24 h after SIV infection. The level of SIV production from SFV-1 vector transduced cells was monitored by RT enzymatic activity and the amount of capsid p27 was analyzed by the SIV antigen capture assay kit (Coulter Corporation, Miami, FL) according to the manufacturer's directions.
